Clinical Pediatrics

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to browse AJSM online!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gillman, S. A.
Right arrow Articles by Kramer, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gillman, S. A.
Right arrow Articles by Kramer, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Clinical Pediatrics, Vol. 41, No. 9, 687-696 (2002)
DOI: 10.1177/000992280204100908

The Health-Related Quality of Life Effects of Once-Daily Cetirizine HCl Syrup in Children with Seasonal Allergic Rhinitis

Sherwin A. Gillman, MD

CHOC Pediatric Subspecialty Faculty, Division of Allergy and Immunology, Children's Hospital of Orange County, Orange, CA

Mark Blatter, MD

Primary Physicians Research, Pittsburgh, PA

John J. Condemi, MD

Allergy, Asthma and Immunology of Rochester, Rochester, NY

Millicent Collins, MD

Department of Pediatrics, DC General Hospital, Washington, DC

Abayomi O. Olufade, PharmD, MS

Pfizer Inc., New York

Nancy Kline Leidy, PhD

MEDTAP International Inc., Bethesda, MD

Douglass Chapman, MS

Benjamin Kramer, MD

Pfizer Inc., New York

Seasonal allergic rhinitis (SAR) can adversely impact children's physical, psychological, and social functioning and well-being, that is, their health-related quality of life (HRQL). This study assessed HRQL in children 6 to 11 years treated with cetirizine HCl syrup, while concurrently assessing symptomatic relief and safety. In an open-label, non-comparative study, 544 children from 124 centers in the United States were instructed to take cetirizine HCl syrup (10 cc of 1 mg/mL) each evening for 4 weeks. Children experienced statistically significant improvements in HRQL with significant reductions in mean symptom score (p<0.001) during the treatment period. Results were consistent across age groups (6-7, 8-9, 10-11 years). These results suggest that the symptomatic relief and tolerability profile of cetirizine HCl syrup daily translates into improvements in the HRQL of children with SAR. This 4-week open label study is among the first to evaluate the effect of antihistamine treatment on HRQL outcomes in children.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?